Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations

BACKGROUND: The detection of V600E BRAF mutations has fundamental clinical consequences as the treatment option with BRAF inhibitors such as vemurafenib or dabrafenib yields response rates of ∼48%. Heterogeneity with respect to BRAF mutation in different metastases has been described in single cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinzerling, L, Baiter, M, Kühnapfel, S, Schuler, G, Keikavoussi, P, Agaimy, A, Kiesewetter, F, Hartmann, A, Schneider-Stock, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844905/
https://www.ncbi.nlm.nih.gov/pubmed/24196789
http://dx.doi.org/10.1038/bjc.2013.622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844905/
https://www.ncbi.nlm.nih.gov/pubmed/24196789
http://dx.doi.org/10.1038/bjc.2013.622

Ejemplares similares